News
Displaying 21–30 of 525
-
Research News
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
Research News
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Foundation News
The Foundation Fighting Blindness develops strategic partnership with Alma, a network of 25,000 mental health professionals dedicated to simplifying access to high-quality, affordable mental healthcare.
-
Foundation News
The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the strong progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
-
Foundation News
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.
-
Atsena Receives $150 Million in New Financing to Advance XLRS and Preclinical Gene Therapy Programs
Research NewsThe company has reported encouraging results from its LCA1 and XLRS gene therapy clinical trials.
-
Honoring the Legacy of Bob Reintsma: A Visionary in the Fight Against Blinding Diseases
Foundation NewsBob Reintsma was fiercely passionate about driving treatments and cures for blinding diseases for most of his life. The Foundation is extremely grateful for Bob’s dedication to our mission and legacy of generosity.
-
Luxa Reports Vision Improvements in Clinical Trial of its RPE Stem Cell Therapy for Dry AMD
Research NewsPatients with worse vision at trial enrollment had greatest vision improvements.
-
Neurotech’s Encapsulated Cell Technology Receives FDA Approval for Treatment of MacTel
Research NewsThe technology was previously funded by the Foundation for the treatment of retinitis pigmentosa and dry age-related macular degeneration.
-
Foundation News
With nearly two decades of leadership in vision and neuroscience research and a committed tenure with the Foundation, Dr. Laster will spearhead the Foundation’s scientific strategy in her new role.
